12
Fri, Jul
68 New Articles

B2RLaw Advises Moffitt Cancer Center and OncoBay Clinical on Clinscience PLN 150 Million Investment in OncoBay

B2RLaw Advises Moffitt Cancer Center and OncoBay Clinical on Clinscience PLN 150 Million Investment in OncoBay

Poland
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

B2RLaw has advised the Moffitt Cancer Center and its for-profit subsidiary OncoBay Clinical on Clinscience's USD 33.5 million investment in OncoBay.

Clinscience is a global clinical research organization based in Warsaw, Poland. 

According to B2RLaw, “the investment will give Clinscience’s parent company, the NEUCA Group, a majority equity stake in OncoBay. The total consideration was USD 33.5 million (approximately PLN 150 million).”

According to the firm, “OncoBay is a boutique clinical research organization specializing in immuno-oncology and cell therapy, offering full-service custom curated CRO solutions for global pharmaceutical and biotech companies. The Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment and research center located in Tampa, Florida. Established in 1981 by the Florida Legislature, the hospital opened in October 1986 on the University of South Florida’s campus.”

The NEUCA Group operates in the wholesale distribution of pharmaceutical products in Poland.

B2RLaw’s team included Partner Agnieszka Hajos-Iwanska, Counsels Luiza Wyrebkowska and Piotr Leonarski, and Junior Associate Krzysztof Judasz.

B2RLaw did not respond to our inquiry on the matter.

Our Latest Issue